Clinical Trial Update: Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

View source ↗

Summary

A clinical trial update reports changes in visceral adipose tissue and liver associated with semaglutide use in individuals with chronic kidney disease due to t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease in Type 2 Diabetes
• Obesity
• Overweight

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: University of Alberta | Conditions: Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight | Status: NOT_YET_RECRUITING